Work

Supply and Clinical Application of Actinium-225 and Bismuth-213

Year: 2020

Type: review

Abstract: The recent development of 225Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters 225Actinium and its daughter nuclide 213Bismuth include the therapy of brain tumors, bladder cancer, neuroendocrine tumors, and leukemia. This paper will provide a brief overview on the current status of the clinical development of compounds labelled with 225Ac or 213Bi and describe the various production routes that are in place or are under development to meet the increasing demand for these radionuclides.

Source: Seminars in Nuclear Medicine

DOI: 10.1053/j.semnuclmed.2020.02.003

Authors: Alfred Morgenstern, Christos Apostolidis, Frank Bruchertseifer

Institutions: European Commission, Joint Research Centre, Joint Research Centre, Joint Research Centre

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,200